Course Objectives
Overall Goal:
The 22nd Annual DMPK Conference will discuss the current issues in selecting potential new therapeutic entities for drug development and current issues in drug metabolism, drug transport, pharmacokinetics, and pharmacodynamics.
Conference objectives:
The objectives for this conference include:
- To provide a forum to discuss the role of absorption, distribution, metabolism, and elimination (ADME) in the pharmacokinetics and pharmacodynamics of new product candidates, including small molecular entities, biologicals, and biotechnology-derived molecules.
- To facilitate insight into problems and issues encountered during the drug discovery and lead optimization processes and with the interface between drug discovery and development..
- To discuss current regulatory issues affecting preclinical and clinical development, within the United States and globally.
- To identify processes for improving the identification of successful drug candidates using ADME technologies, in-vitro/in-vivo relationships, and modeling and simulation.
- To discuss current ADME experimental systems and their applicability in R&D activity.
- To gain insight on the drug-development process from various perspectives, including industry, academia, and regulatory agencies.
- To discuss new technologies and processes that help describe the ADME characteristics of potential therapeutic entities and mechanisms of biotransformation.
Poster Session:
The Planning Committee for the 22nd Annual Land O’Lakes Conference on Drug Metabolism and Pharmacokinetics and Applied Drug Development, invites interested parties to submit research poster abstracts for the 2019 Conference Poster Session on Wednesday, September 18, at the Fluno Center, Madison, Wisconsin.
All abstracts must be submitted via email to the University of Wisconsin by Monday, July 15, 2019. Proposals will be reviewed and evaluated by a review panel of Planning Committee members. Acknowledgement of receipt will be sent by e-mail, as well as notification of the acceptance or rejection of abstracts to primary presenters by August 5. Please do not call the University of Wisconsin to find out the status of your abstract(s).
To submit a poster for consideration, at least one author must be registered for the conference. If the poster is not accepted, authors have the right to cancel their registration by the registration deadline of August 26 and will receive a full refund. Any author present at the Conference must be registered for the entire Conference.
Accepted abstracts will be placed on the University of Wisconsin Web site by August 12, 2019.
Call for Posters 2019DMPK
September 2018 LOL poster abstracts
Instructors
Seth Bell, PhD, Senior Research Chemist, Charles River Labs, Cleveland, OH
Robert Bondi, PhD, GlaxoSmithKline
Kari Fonseca, PhD, Scientist, Pfizer Inc., New London, CT
Matt Gevaert, PhD, CEO, Kiyatec, Greensville, SC
James Gosset, PhD, DMPK Senior Principal Scientist, Pfizer Inc., Boston, MA
Ryan Hansen, PhD, Senior Research Advisor, Eli Lilly and Co, Salt Lake City, UT
Edward Kelly, PhD, Associate Professor, Dept. of Pharmaceutics, University of Washington, Seattle, WA
John Kendrick, PhD, Director, Global Metabolism & Pharmacokinetics, Covance, Madison, WI
J. Steven Leeder, PharmD, PhD, Marion Merrell Dow Endowed Chair in Pediatric Precison Therapeutics, Associate Chair-Research, Department of Pediatrics Deputy Director, Children's Research Institute, Children's Mercy, Kansas City, KS
Mingguang Li, PhD, Lead Staff Scientist, Pharmacokinetics, Covance, Madison, WI
Donald L. McKenzie PhD, Covance Laboratories, Madison, WI
John Morrison, PhD, Senior Research Investigator, Bristol-Myers Squibb, Princeton, NJ
Miaoran Ning, PhD, Senior Scientist, PBPK modeler, AbbVie, Lake Bluff, IL
Andrew Parkinson, PhD, CEO, XPD Consulting, Shawnee, KS
Colin Philips, PhD, AbbVie
Diane Ramsden, PhD, Senior Scientist, Alnylam Pharmaceuticals, Boston, MA
Hong Shen, PhD, Bristol-Myers Squibb, Wallingford, CT
Mohammed Shebley, PhD, Director, Clinical PKPD, AbbVie, Chicago, IL
Craig Simmons, PhD, Distinguished Professor of Mechanobiology, University of Toronto, Toronto, ON
Paul Scott Stevens, MSc, DMPK Director, GlaxoSmith Kline, Stevenage, UK
Jennifer Thomas, PhD, ADME/DMPK, Charles River Labs, Ashland, OH
Kelly Turner, PhD, Principal Research Scientist, Eli Lilly & Co. Indianapolis, IN
Brandon Turunen, PhD, Head, Synthetic Immunology, GlaxoSmithKline, Philadelphia, PA
Maciej Zamek-Gliszczynski, PhD, Director, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA
Accommodations
Hotel accommodations are the responsibility of the registrant.
Fluno Center
(conference location)
601 University Ave
Madison, WI 53715
608.441.7148 877.773.5866
$143.00
Release date: August 11, 2019
Booking link
Hampton Inn
(5 blocks away)
440 West Johnson St
Madison, WI 53703
608.255.0360
$169.00
Release Date: August 8, 2019
Group Name: Drug Metabolism Conference Group Code: DRG
Booking link
DoubleTree by Hilton Madison
(4 blocks away)
525 West Johnson St
Madison, WI 53703
608.251.5511
$189.00
Release Date: August 9, 2019
Booking link
The Lowell Center
(2 blocks away)
610 Langdon St
Madison, WI 53703
608.256.2621
$115.00
Group Code: LANDDMPK
Release Date: August 9, 2019
Booking link
Graduate Hotel
(3 blocks away)
601 Langdon Street
Madison, WI 53703
608.257.4391
Rate: $189.00
Room block held until July 29
Booking link
